Thousands of men battling prostate cancer are set to gain access to a life-extending drug on the NHS following a significant ...

NHS England has announced that men whose high-risk prostate cancer has not yet spread will be able to receive the drug, ...

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...

The decision means Northern Ireland remains the only country in the UK where patients with this stage of prostate cancer are ...

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Men with high‑risk locally advanced prostate cancer in England will soon be offered the drug abiraterone on the NHS, ...

Thousands more men with prostate cancer will be eligible for a life-extending drug on the NHS. The move means the drug, known ...

Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...

Prostate cancer has overtaken breast cancer to become the most common form of the disease in the UK for the first time.